NASDAQ · GLSI
Healthcare · Biotechnology
$15.06
Up+$0.39 (+2.59%)
Updated Sep 12, 2026, 1:04 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GLSI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning GLSI.
GLSI research
Company profile and research snapshot.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 30, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 23, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 30, 2026
STAFFORD, Texas, April 30, 2026 -- Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track...
Benzinga · Mar 19, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Benzinga · Mar 18, 2026
Benzinga · Mar 17, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLSI.
